IperionX Limited Stock 12‑Month Price Target Cut to $41.45, Implies 146% Upside

Iperionx Ltd. [IPX] began commercial titanium production, expanded capacity, and secured U.S. government contracts. The company reported a net loss of $66.8M, attributing it to ramp-up costs, but highlighted strong funding and project economics for future growth.

IperionX (IPX) validated its GenX titanium production platform, achieving a sixfold increase in throughput and 75% energy reduction. The system processed 500 kg of titanium powder in four runs. The US Army awarded IPX a $99M contract for domestic titanium production. IPX aims to scale the technology for broader applications.

IperionX Ltd (ASX: IPX) validated its GenX™ platform, achieving six times higher throughput and over 75% lower power consumption in titanium production. The company produced 500 kg of titanium powder, meeting quality standards. IperionX plans to optimize the process for industrial-scale production, supported by a US$99 million U.S. Army contract.

IperionX Limited (NASDAQ: IPX) said it plans to redomicile its ultimate parent to Texas, subject to approvals, and expects the new U.S. parent’s common stock to list directly on Nasdaq, replacing its ADS structure. The company also appointed Michael J. Loparco as an independent non-executive director effective Aug. 3, 2026.

Avingtrans (AVG) raised about £21m via a placing of 3,309,000 new shares at 630p each, according to Yahoo Finance. The funds support expansion at its Michigan nuclear facility. Nuclear revenues are about £35m, with a target of about £90m by 2031. Shares rose 4.76% to 660p.

IperionX raised about $50 million via a public offering, selling 2.275 million shares at $21.98 each, to expand U.S. titanium manufacturing. The company plans to increase capacity in Virginia, continue its Tennessee Camden Titanium Project, and fund low-carbon titanium R&D, according to the company. Cantor Fitzgerald led, with Roth Capital Partners and B. Riley Securities co-managing.